Navigation Links
New Webinar Hosted by Xtalks Prepares Manufacturers for AMNOG Regulations and the Future of Access and Pricing

Toronto, Canada (PRWEB) August 25, 2014

Introduction of the Pharmaceutical Market Restructuring Act (AMNOG) in 2011 and the resulting requirements for benefit assessment have fundamentally changed the conditions of market access and pharmaceutical pricing in Germany. The aim of this mandatory evaluation of clinical evidence was to limit the cost of pharmaceuticals and tackle the price monopoly of drug manufacturers in Germany.

While this has successfully been achieved, it has also brought with it further implications beyond the immediate German market, particularly for those countries that use Germany as a price reference. The open nature in which the clinical evidence and especially the critical aspects in these assessments is shared publically has potential impact on a product’s value story with payers in many other jurisdictions. For organizations working in this market or utilizing German price points for market access strategy, understanding these interconnections is critical.

Key take aways of this program include:

  •     Understanding of current AMNOG process
  •     Implications of AMNOG evaluation
  •     Impact of publically available assessment on value story
  •     Overview of price discount trends, both average and unique examples
  •     Future growth beyond current AMNOG framework

For more information or to register for this webinar, visit: AMNOG – German Regulation in the Past, Present and Future.

About Xcenda and Herescon
Xcenda is a strategic consulting firm with 20 years of experience applying real-world expertise in health economics and outcomes research, reimbursement, health policy, market research, and market access strategy. In December of 2013, Herescon GmbH, one of the largest research and consulting boutiques in Germany focused on market access and health economics services, joined this experienced team. As part of AmerisourceBergen Corporation, a leading global healthcare solutions company, the combined bench of Xcenda and Herescon consultants supports pharmaceutical companies as well as emerging pre-commercialization phase firms with challenges such as developing an evidence package to optimize access in key global markets, predicting product performance, and identifying reimbursement strategies and programs to maximize patient access. From development through market maturity, these collaborative partners help manufacturers identify, demonstrate, and deliver their brand’s value proposition to key healthcare stakeholders. For more information visit on Xcenda, visit For more information on Herescon, visit

About Xtalks
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks, visit
For information about hosting a webinar, visit

Michelle Tran
Tel: +1 (416) 977-6555 ext 352
Email: mtran(at)xtalks(dot)com

Read the full story at

Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related biology technology :

1. Efficient Identification of Protein-Coding Variants in a Model Organism Through Exome Sequencing, New Webinar Hosted by Xtalks
2. Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks
3. Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks
4. China – Land of Opportunities & Challenges for the Clinical Research Industry, New Webinar Hosted by Xtalks
5. The Voice of the Patient in Clinical Trials: Hearing It, Understanding It, New Webinar Hosted by Xtalks
6. Protocol Pooling and Point of Distribution (PoD) Clinical Labeling, Live Webinar Hosted by Xtalks
7. Defining Low Cost in Your Solution for Future Facilities, New Webinar for Pharma, Biotech, Medical Device and Healthcare Companies, Hosted by Xtalks
8. The Evolution of RNA-Sequencing, Upcoming Live Webinar August 22 hosted by Xtalks
9. Leveraging ‘Big Data’ - Methodological Considerations in Health Services Research, New Webinar Hosted by Xtalks
10. Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks
11. Implementing Risk-based Monitoring, Using Oncology Examples, New Webinar July 31st Hosted by Xtalks
Post Your Comments:
(Date:12/1/2015)...  Symic, a clinical-stage biotherapeutics company developing multiple compounds ... announced that it has secured $25 million in a ... its lead candidates SB-030 and SB-061. The financing was ... all existing major investors, as well as several new ... by Symic to over $43 million since being founded ...
(Date:12/1/2015)... Texas (PRWEB) , ... December 01, 2015 , ... Matthew ... his new post, VerMilyea will oversee all IVF lab procedures as well ... and fertility preservation. , “We traveled 7,305 miles to Auckland, New Zealand to bring ...
(Date:11/30/2015)... ... November 30, 2015 , ... Global Stem Cells Group ... in the Santiago Marriott. The Global Stem Cells Group GMP facility is equipped ... of qualified medical researchers and practitioners, experienced in administering stem cell protocols using ...
(Date:11/30/2015)... -- Partnership includes an MPP ... the u niversity , s Solid Drug ... cale - up through ... Africa , where licensees based anywhere in the world will have the right ... Africa , where licensees based anywhere in the world will have ...
Breaking Biology Technology:
(Date:11/2/2015)...  SRI International has been awarded a contract of ... to the National Cancer Institute (NCI) PREVENT Cancer Program ... modern testing and support facilities, and analytical instrumentation to ... studies to evaluate potential cancer prevention drugs. ... Drug Development Program is an NCI-supported pipeline to bring ...
(Date:10/29/2015)... 2015  Connected health pioneer, Joseph C. Kvedar ... technology-enabled health and wellness, and the business opportunities that ... The Internet of Healthy Things . Long before ... existed, Dr. Kvedar, vice president, Connected Health, Partners HealthCare, ... moving care from the hospital or doctor,s office into ...
(Date:10/27/2015)... 27, 2015 Synaptics Inc. (NASDAQ: SYNA ), ... Google has adopted the Synaptics ® ClearPad ® ... power its newest flagship smartphones, the Nexus 5X by ... --> --> Synaptics works ... strategic collaboration in the joint development of next generation ...
Breaking Biology News(10 mins):